Novo

Novo is a shorthand reference to Novo Nordisk, a Danish multinational pharmaceutical company that develops and manufactures diabetes and obesity medications.

Why it’s in the news: It is in the news due to its recent licensing deals for obesity treatments and its role in boosting the Chinese biotech sector.

Latest on Novo

• A IA criou um novo cargo no C-level — e o Brasil lidera em conflitos sobre a função
• Snapdragon X2 Plus puts AI at the heart of Lenovo’s new Yoga Slim 7x
• Novo Nordisk strikes second licensing deal since frosty capital-markets day
• STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
• AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
• After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Connections

16 entities linked to Novo across the news graph.